Loading market dashboard
Terns Pharmaceuticals, Inc.
TERNHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Tern PLC (AIM:TERN) shares surged some 30% higher, to 1.18p, after it increased exposure to Talking Medicines - an AI company aiming to help healthcare advertising agencies analyse conversational data for pharmaceutical clients - through around £270,000 of new unsecured convertible loan notes, using a structure that gives the AIM-listed investor roughly twice the principal exposure of its fresh cash and cancelled debt contribution. The investment company, which backs early-stage Internet of Things technology businesses, said the CLNs were issued after it agreed to cancel around £87,000 owed by Talking Medicines and put in a further £48,000 of new funds.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to be.
Merck retains a 'strong buy' rating, driven by proactive oncology pipeline expansion to offset KEYTRUDA patent expiration in 2028. Acquisition of Terns Pharmaceuticals brings TERN-701, a best-in-disease oral BCR-ABL1 TKI for CML, with multibillion-dollar potential and recent FDA Breakthrough Therapy Designation. The company advances the KEYTRUDA family with QLEX SC formulation and combination therapies, targeting new PDUFA approvals in bladder and renal cancers through 2026.
Merck MRK is set to report its first-quarter 2026 earnings on April 30, before market open. The Zacks Consensus Estimate for first-quarter top line is pegged at $15.90 billion, while the same for the bottom line stands at a loss of $1.51 per share.
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs) Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
All told, the transaction is valued at around $6.7 billion. If all goes well, it'll close this quarter.
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Te.
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
Capricorn Fund Managers Ltd bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 151,436 shares of the company's stock, valued at approximately $6,118,000. Terns Pharmaceuticals makes up approximately 1.5% of
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
Pre-Market Stock Futures: Futures are trading higher this morning after reports are circulating that President Trump wants to end the war soon. This comes after Monday's session, which saw three of the four major indices close lower, while oil traded above $100 for the first time since the summer of 2022. Conflicting headlines flew around;... Here Are Tuesday's Top Wall Street Analyst Research Calls: Arista Networks, Block, Colgate-Palmolive, Digital Realty, Emerson Electric, MiniMed, Shake Shack, and More.
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil on any given day. Those two items have dictated the direction of stocks, bonds, precious metals, and crypto since... Here Are Friday's Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More.
MRK's $6.7B Terns buyout is set to add a promising leukemia drug candidate, boosting its oncology pipeline as it prepares for Keytruda's patent cliff.
E. Ohman J or Asset Management AB lessened its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) by 79.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 21,202 shares of the company's stock after selling 81,208 shares during the quarter. E. Ohman J or
Shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday. The company traded as high as $52.98 and last traded at $52.86, with a volume of 81314600 shares trading hands. The stock had previously closed at $50.00. Trending Headlines about Terns Pharmaceuticals Here are
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
NEW YORK, March 25, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) related to its sale to Merck Sharp & Dohme LLC.
4:15pm: In the green US stocks finished Wednesday’s session higher on hopes peace talks will soon resolve the US-Iran conflict. The Nasdaq was up 0.8% at...
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.7 billion. This marks Merck's third multibillion-dollar acquisition in the past year as the company looks to strengthen its portfolio ahead of its top-selling cancer drug Keytruda losing patent protection in 2028.
MILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) to Merck for $53.00 per share in cash. Halper Sadeh encourages Terns shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Terns and its board of directors violated the fed.
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda.
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML
RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash a.
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) shares reached a new 52-week high during trading on Friday. The company traded as high as $49.53 and last traded at $49.13, with a volume of 3613141 shares changing hands. The stock had previously closed at $47.78. Wall Street Analysts Forecast Growth Several equities research analysts
Superstring Capital Management reduced its stake in Terns by 345,869 shares during the fourth quarter; the estimated trade value was $7.99 million based on quarterly average prices. Meanwhile, the quarter-end position value declined by approximately $12.00 million, reflecting both trading and stock price movements.
Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in the fourth quarter. The quarter-end position value increased by $181.80 million as a result of this purchase, which created a new stake for the fund.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 9,767 call options on the stock. This represents an increase of 501% compared to the typical volume of 1,624 call options. Terns Pharmaceuticals Price Performance NASDAQ: TERN opened at $46.52 on Friday. The business has a
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Dynamic Technology Lab Private Ltd increased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) by 237.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,576 shares of the company's stock after purchasing an additional 46,831 shares during the quarter. Dynamic Technology Lab
Why momentum investing often outperforms buy-and-hold - and how stage analysis identifies breakout stocks early.
DLD Asset Management LP cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ: TERN) by 73.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company's stock after selling 27,047 shares during the quarter. DLD Asset
Stock market volatility is rising as algorithms react instantly to global events, forcing investors to rethink traditional strategies.
